# Virdante Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virdante-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Total disclosed funding: $78M
- Latest round: Series A (Nov 25, 2009)
- Investors on record: 6

## About

Founded in 2007 and based in Massachusetts, US, Virdante Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of autoimmune and inflammatory disorders.

## Funding rounds

- Series A, Nov 25, 2009, $30M — Thomas, McNerney & Partners, Venrock, Clarus Ventures, OUP (Osage University Partners), MedImmune Ventures, Biogen Idec New Ventures
- Series A, Oct 30, 2009, $48M — Thomas, McNerney & Partners, Venrock, Clarus Ventures, OUP (Osage University Partners), MedImmune Ventures, Biogen Idec New Ventures

## Investors

- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series A
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series A
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series A